Company news

Oryzon Genomics SA news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2025

May 12, 2025

ORYZON Awarded €13.26 Million Through the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project)

May 8, 2025

ORYZON Raises €30 Million in Capital Increase

April 24, 2025

ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clinical Trial of Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer

April 15, 2025

ORYZON to Provide Corporate Progress Updates at Several Events in March-April

March 14, 2025

Oryzon Announces Publication of Study on Phelan-McDermid Syndrome (PMS) Patients, a Form of Autism, Paving the Way for a Novel Personalized Medicine Approach with Vafidemstat

March 5, 2025

Oryzon Defines Phase III Trial Endpoints for Agitation and Aggression in BPD with Input From New Clinical Advisory Board

March 3, 2025

ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting

February 28, 2025

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2024

February 27, 2025

ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders’ Meeting

January 27, 2025

ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome

January 23, 2025

ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor

January 21, 2025

ORYZON Announces First Patient Dosed in NCI-Sponsored Iadademstat in Combination With Venetoclax and Azacitidine Clinical Trial in First Line Acute Myeloid Leukemia

January 13, 2025

ORYZON to Provide Corporate Progress Updates at Several Events in January-February

January 10, 2025

ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024

October 24, 2024

ORYZON Presents the Final Data From PORTICO, a Global Phase IIb Vafidemstat Trial in Borderline Personality Disorder (BPD), at the European College of Neuropsychopharmacology (ECNP) Congress

September 23, 2024

ORYZON Receives “Intention to Grant” Communication for Patent Relating to the Use of Vafidemstat in Borderline Personality Disorder

September 11, 2024

ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in First-Line Acute Myeloid Leukemia

September 9, 2024

ORYZON to Provide Corporate Progress Updates at Several Events in September

August 29, 2024

ORYZON reports financial results and corporate update for half-year ending June 30, 2024

July 31, 2024

ORYZON Receives “Decision to grant” for Two Important Patents for Vafidemstat in Japan

July 8, 2024

ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders

June 28, 2024

ORYZON Presents Preliminary Data From Ongoing Phase Ib FRIDA Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory FLT3-mut AML Patients at EHA-2024

June 14, 2024

ORYZON Announces Journal Publication of Final Phase IIa ALICE Results with Iadademstat in The Lancet Hematology

June 3, 2024

ORYZON to Provide Corporate Progress Updates at Several Events in June

May 30, 2024

ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer

April 8, 2024

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023

February 26, 2024

ORYZON to Provide Corporate Progress Updates at Several Events in February-March

February 5, 2024

ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024

January 19, 2024

ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)

January 5, 2024

ORYZON to Provide Corporate Progress Updates at Several Events in January

January 3, 2024

ORYZON Awarded with a Grant for ORY-4001 From the ALS Association in the U.S.

December 4, 2023

ORYZON Announces a New Financing Through a Convertible Bond Program For a Total Amount of Up To €45 Million

November 21, 2023

ORYZON Announces Last Patient Last Visit in its Phase IIb PORTICO Study for Borderline Personality Disorder (BPD)

November 7, 2023

ORYZON to Provide Corporate Progress Updates at Several Events in November

November 6, 2023

ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023

October 27, 2023

ORYZON presents blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder

October 10, 2023

ORYZON Receives Two Grants to Further Explore the Role of Epigenetic Targets in the Treatment of Neuronal Pathologies

October 3, 2023

ORYZON to Provide Corporate Progress Updates at Several Events in October

October 2, 2023

ORYZON to Give Updates on Corporate Progress in September

September 5, 2023

ORYZON Reports Financial Results and Corporate Updates for Half-Year Ending June 30, 2023

July 24, 2023

ORYZON Announces Voting Results from its 2023 Annual General Meeting of Shareholders

June 27, 2023

Positive Preclinical Data of ORY-4001 for the Treatment of Charcot-Marie-Tooth (CMT) Disease Presented at the 2023 Peripheral Nerve Society (PNS) Annual Meeting

June 21, 2023

ORYZON to Present Positive Preclinical Efficacy Data of ORY-4001 in Charcot-Marie-Tooth (CMT) Disease at the 2023 Peripheral Nerve Society (PNS) Annual Meeting

May 30, 2023

ORYZON to Present Trial in Progress Phase Ib FRIDA Study at the Upcoming 2023 ASCO Annual Meeting

May 17, 2023

ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2023

May 10, 2023

ORYZON to Give Updates on Corporate Progress in May-June

May 9, 2023

ORYZON Announces Positive Results from Planned Interim Analysis of PORTICO, a Phase 2b Adaptive Trial in Borderline Personality Disorder

April 3, 2023

ORYZON Announces First Patient In in FRIDA, a Phase Ib Trial With Iadademstat in Relapsed/Refractory FLT3-mutant Acute Myeloid Leukemia Patients

March 15, 2023

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2022

February 17, 2023

← Newer news releases · Older news releases →

Decks

The 5 newest of 18 decks. Every deck is listed under its year.